Search research articles
Contact Us
Filters
Showing results (21-30 of 208) with videos related to
Page
of 21
Sort By:
Nuclear Medicine and Biology
|
September 13, 2016
Radioligand therapy with <sup>177</sup>Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use
Hojjat Ahmadzadehfar, Markus Essler, Michael Schäfers, et al.
Clinical Nuclear Medicine
|
November 8, 2016
Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis
Anna Yordanova, Karin Mayer, Markus Essler, et al.
The Biochemical Journal
|
October 22, 2011
Thrombin-induced shedding of tumour endothelial marker 5 and exposure of its RGD motif are regulated by cell-surface protein disulfide-isomerase
Mario Vallon, Philipp Aubele, Klaus-Peter Janssen, et al.
Nuklearmedizin. Nuclear Medicine
|
October 2, 2024
Toward the future of nuclear medicine: How young professionals are getting involved and what plans they have
Conrad-Amadeus Voltin, Sarah Spreckelmeyer, Markus Essler, et al.
Seminars in Nuclear Medicine
|
December 18, 2019
PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients
Hojjat Ahmadzadehfar, Kambiz Rahbar, Markus Essler, et al.
Experimental Cell Research
|
October 27, 2009
Tumor endothelial marker 5 expression in endothelial cells during capillary morphogenesis is induced by the small GTPase Rac and mediates contact inhibition of cell proliferation
Mario Vallon, Franziska Rohde, Klaus-Peter Janssen, et al.
Journal of Clinical Medicine
|
September 19, 2019
Therapy of Patients with Neuroendocrine Neoplasia-Evidence-Based Approaches and New Horizons
Ralph A Bundschuh, Bilel Habacha, Susanne Lütje, et al.
PET Clinics
|
September 17, 2018
Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning
Hojjat Ahmadzadehfar, Markus Essler, Kambiz Rahbar, et al.
Clinical Nuclear Medicine
|
February 25, 2016
Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617
Carl Diedrich Schlenkhoff, Eberhard Knüpfer, Markus Essler, et al.
Nuklearmedizin. Nuclear Medicine
|
December 18, 2020
"COVID-19 Pandemic as stimulator to Re-Establish Nuclear Medicine as Clinical Specialty" based on a report of Prof. Dr. Ignasi Carrio
Ignasi Carrio, Markus Essler, Lutz S Freudenberg, et al.
Page
of 21
Search research articles
Search
Showing results (21-30 of 208) with videos related to
Sort By:
Page
of 21
Nuclear Medicine and Biology
|
September 13, 2016
Radioligand therapy with <sup>177</sup>Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use
Hojjat Ahmadzadehfar, Markus Essler, Michael Schäfers, et al.
Clinical Nuclear Medicine
|
November 8, 2016
Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis
Anna Yordanova, Karin Mayer, Markus Essler, et al.
The Biochemical Journal
|
October 22, 2011
Thrombin-induced shedding of tumour endothelial marker 5 and exposure of its RGD motif are regulated by cell-surface protein disulfide-isomerase
Mario Vallon, Philipp Aubele, Klaus-Peter Janssen, et al.
Nuklearmedizin. Nuclear Medicine
|
October 2, 2024
Toward the future of nuclear medicine: How young professionals are getting involved and what plans they have
Conrad-Amadeus Voltin, Sarah Spreckelmeyer, Markus Essler, et al.
Seminars in Nuclear Medicine
|
December 18, 2019
PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients
Hojjat Ahmadzadehfar, Kambiz Rahbar, Markus Essler, et al.
Experimental Cell Research
|
October 27, 2009
Tumor endothelial marker 5 expression in endothelial cells during capillary morphogenesis is induced by the small GTPase Rac and mediates contact inhibition of cell proliferation
Mario Vallon, Franziska Rohde, Klaus-Peter Janssen, et al.
Journal of Clinical Medicine
|
September 19, 2019
Therapy of Patients with Neuroendocrine Neoplasia-Evidence-Based Approaches and New Horizons
Ralph A Bundschuh, Bilel Habacha, Susanne Lütje, et al.
PET Clinics
|
September 17, 2018
Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning
Hojjat Ahmadzadehfar, Markus Essler, Kambiz Rahbar, et al.
Clinical Nuclear Medicine
|
February 25, 2016
Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617
Carl Diedrich Schlenkhoff, Eberhard Knüpfer, Markus Essler, et al.
Nuklearmedizin. Nuclear Medicine
|
December 18, 2020
"COVID-19 Pandemic as stimulator to Re-Establish Nuclear Medicine as Clinical Specialty" based on a report of Prof. Dr. Ignasi Carrio
Ignasi Carrio, Markus Essler, Lutz S Freudenberg, et al.
Page
of 21